At least two pathways of caspase activation have been delineated, including extrinsically and intrinsically stimulated cascades (1) (2) (3) . The extrinsic pathway involves apoptosis mediated by cell surface death receptors, such as Fas, tumor necrosis factor receptor, or TRAIL 1 receptor. Fas stimulation results in oligomerization of the receptors and recruitment of the adapter protein Fas-associated death domain (FADD) and caspase-8, forming a death-inducing signaling complex (DISC) (4) . Autoactivation of caspase-8 at the DISC is followed by activation of effector caspases, including caspase-3, -6, and -7, which function as downstream effectors of the cell death program. The intrinsic pathway is mediated by diverse apoptotic stimuli, which converge at the mitochondria. Release of cytochrome c from the mitochondria to the cytoplasm initiates a caspase cascade. Cytosolic cytochrome c binds to apoptosis proteaseactivating factor 1 (Apaf-1) and procaspase-9, generating a DISC-like complex, "apoptosome" (5, 6) . Within the apoptosome, caspase-9 is activated, leading to processing of caspase-3. The two pathways of apoptosis, extrinsic/death receptor and intrinsic/mitochondrial, converge on caspase-3 and subsequently on other proteases and nucleases that drive the terminal events of programmed cell death. The significance of Apaf-1, caspase-9, and caspase-3 for the execution of apoptosis has been confirmed by genetic studies in mice (7) (8) (9) . Cells derived from Apaf-1, caspase-9, and caspase-3 knockout mice demonstrated defects in response to a variety of apoptotic stimuli. However, T lymphocytes from mice lacking Apaf-1 or caspase-9 were susceptible to apoptosis signaled via Fas or tumor necrosis factor receptors (10, 11) . Also, cytochrome cdeficient cells were susceptible to death receptor-mediated apoptosis (12) . These findings support the concept that the two apoptotic pathways are discrete and function in parallel. However, each of the pathways is amplified by activated components of the "other" pathway. In cases of low initial caspase-8 activation, the direct effect of caspase-8 on caspase-3 is amplified by a mitochondrial loop (1) . In this scenario, caspase-8 cleaves off an N-terminal fragment of Bid, allowing the tBid to translocate to the mitochondria and induce cytochrome c release (13) (14) (15) . Also, the intrinsic pathway is amplified by components of the death receptor cascade, as cytostatic drugs have been reported to activate caspase-8 secondarily to mitochon-drial damage (16, 17) . Currently, cross-talk between the extrinsic and intrinsic pathways has been observed mainly as an amplification loop at the level of execution, but not initiation, of each of the cascades. Also, tumor cell lines studied for resistance to apoptosis were resistant to either the death receptor or the mitochondrial pathway but not cross-resistant to both pathways (18) . Cross-resistance has been observed in cells overexpressing an inhibitor, such as X-linked inhibitor of apoptosis (XIAP/hILP), which targets downstream effector molecules, such as caspase-3, shared by both pathways (19 -22) . Also, members of the Bcl-2 family, which play a major role in control of the mitochondria-dependent apoptotic pathway (23) , were reported to protect some cell lines and tissues from Fasinduced apoptosis but not others (24, 25) . However, attenuation of Fas-mediated apoptosis by Bcl-2 might be mediated by inhibition of the mitochondrial amplification loop (1) .
In the current study, we demonstrate the selection of cells resistant to a mitochondrial pathway (intrinsic) by elimination of Fas-sensitive cells (extrinsic pathway). The selection of clonal cell lines completely cross-resistant to inducers of the two apoptotic pathways may suggest the existence of an upstream regulatory component shared by the extrinsic and the intrinsic pathways.
EXPERIMENTAL PROCEDURES
Reagents-Agonistic anti-Fas Ab (CH-11, IgM) was purchased from Upstate Biotechnology Inc. (Lake Placid, NY). Staurosporin and VP-16 were purchased from Sigma. Recombinant caspase-3 and caspase-8, anti-cytochrome c mAb, rabbit anti-caspase-3 Ab, and anti-CD3 -chain mAb (clone 610B10) were purchased from Pharmingen. Anti-hILP/ XIAP mAb (clone 28), anti-caspase-7 mAb (clone 51), and anti-caspase-2 mAb (clone 47) were from Transduction Laboratories (Lexington, KY); rabbit anti-caspase-8 Ab was from StressGen Biotechnology (Victoria BC, Canada); caspase-8-specific mAb (clone 5F7) was from Upstate Biotechnology, Inc.; anti-caspase-9 was from Oncogene (Cambridge, MA); anti-Bcl-2 mAb (clone 100), rabbit anti-Bcl-xL, and goat antiapoptosis-inducing factor (AIF) Ab were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); anti-poly(ADP-ribose) polymerase (PARP) mAb (clone C2-10) was from Enzyme Systems (Livermore, CA); and anti-voltage-dependent anion channel (VDAC) mAb (clone 31HC) was from Calbiochem. Rabbit anti-Bid Ab was generated as described previously (26) . Chloromethyl X-rosamine (CMXRos), nonyl acridine orange (NAO), and hydroethidine (HE) were from Molecular Probes, Inc. (Eugene, OR); phosphatidylethanolamine-conjugated anti-APO2.7, fluorescein isothiocyanate-annexin V and propidium iodide were from CLONTECH (Palo Alto, CA); anti-␤-actin mAb (clone AC-15), horse heart cytochrome c, and dATP were from Sigma; and the TRAIL kit was from Alexis (San Diego, CA).
Preparation of GST-Bax and His-tagged tBid-Mouse Bax-⌬TM (amino acids 1-173) was cloned into pGEX-2T (Amersham Pharmacia Biotech) in fusion with GST protein at its N terminus. Bacterial Escherichia coli strain DH5␣ (Life Technologies, Inc.) was transformed and cultured in LB medium. When A 600 reached 0.7-1.0, isopropyl ␤-Dthiogalactoside was added at 0.1 mM to induce the expression of fusion protein. Bacteria were harvested after 2-3 h of incubation at 37°C and lysed by sonication in lysis buffer (1% Triton X-100, 1 mM EDTA in PBS). After centrifugation, the supernatant was incubated with preswollen glutathione beads for 30 min at 4°C. The beads were then precipitated and washed by centrifugation. GST-BAX-⌬TM was eluted with 5 mM glutathione in 50 mM Tris-HCl, pH 8.0.
Mouse tBid (amino acids 60 -195 ) was cloned into a pET23dwHis vector modified from the pET23d(ϩ) vector (Novagen, WI), in fusion with the 6-histidine tag at its N terminus. Bacteria E. coli strain BL21(DE3) was transformed and cultured at 37°C in Terrific Broth. The induction of expression was started at 0.8 -1.0 A 600 by the addition of 0.4 mM isopropyl ␤-D-thiogalactoside at 37°C for 2-3 h. The bacterial pellets were resuspended and sonicated in the buffer containing 5 mM imidazole, 500 mM NaCl, and 20 mM Tris-HCl, pH 7.9. After centrifugation, the supernatants were passed through a His-Bind nickel-agarose affinity chromatographic column precharged with 50 mM NiSO 4 (Novagen, WI). The columns were washed with the washing buffer containing 60 mM imidazole, 500 mM NaCl, and 20 mM Tris-HCl, pH 7.9. The proteins were eluted with the elution buffer containing 400 mM imidazole, 500 mM NaCl, and 20 mM Tris-Cl, pH 7.9, and were further purified using a Sephadex G-50 column balanced with phosphate-buffered saline.
Cell Lines and Clones-Jurkat T leukemic cell line was obtained from the American Type Culture Collection (ATCC; Manassas, VA). Jurkat cells were grown in RPMI 1640 medium containing 10% fetal calf serum, 2 mM L-glutamine, and 100 units/ml each penicillin and streptomycin (complete medium). The generation of stable cell lines expressing epitope-tagged CrmA or Bcl-2 proteins has been described previously (27) (28) (29) (30) . Transfected cell lines were maintained in complete medium supplemented with 0.5 mg/ml G418 (Life Technologies).
To select for cells resistant to Fas-mediated apoptosis, wild-type Jurkat T cell line was repeatedly exposed to the agonistic anti-Fas mAb, CH-11 (200 ng/ml). Initial treatment induced apoptosis in 99% of the cells. Surviving cells were expanded in culture, and following several consecutive selections with anti-Fas Ab, the cultured cells were further selected by flow cytometry cell sorting to include only Fas-positive cells. Anti-Fas Ab was routinely added to the resistant cell line approximately once a month. Clones of Fas-resistant Jurkat cells were obtained by limiting dilution, and seven of the clonal cell lines were subjected to analysis of mechanisms of resistance. Similar features of resistance to apoptosis were found in all tested clones (as described in this study).
Induction of Apoptosis-Jurkat cells plated at 0.5-1 ϫ 10 6 cells/ml in complete medium were treated with VP-16 (20 -40 M), agonistic antiFas Ab (200 -500 ng/ml), staurosporin (0.5-1 M), or TRAIL (100 nM; enhancer, 2 g/ml) at 37°C for varying lengths of time, as indicated for each experiment. In several experiments, Jurkat cells were treated with cycloheximide (10 g/ml) for 4 h prior to the addition of anti-FasAb, CH-11.
Measurements of Apoptosis-DNA fragmentation was assessed by the JAM assay, in which loss of Cytofluorometric analyses of apoptosis were performed by costaining with propidium iodide and fluorescein isothiocyanate-annexin V conjugate (CLONTECH). Propidium iodide was used to identify breaks in DNA as a feature of late apoptosis, and annexin V was used to assess aberrant phosphatidylserine exposure (32) . The staining was performed according to the manufacturer's directions.
Apoptosis-associated alterations in mitochondria were assessed by flow cytometry analysis using special dyes designed to evaluate mitochondrial events. Disruption of the mitochondrial inner transmembrane potential (⌬⌿m) was measured by the cationic lipophilic fluorochrome CMXRos. Cells were incubated at 37°C for 15 min in the presence of CMXRos (0.1 M, fluorescence at 600 nm) followed by immediate analysis of fluorochrome incorporation (33) .
Generation of superoxide anions was measured by HE (Molecular Probes). Cells were incubated at 37°C for 15 min in the presence of HE (2 M, fluorescence at 600 nm) followed by immediate analysis of fluorochrome incorporation (34) .
Decrease in mitochondrial mass was assessed by NAO (Molecular Probes), reported to measure the inner mitochondrial cardiolipin content (35) . Cells were stained with 0.1 M NAO in RPMI medium for 15 min at 37°C. Cells were washed and immediately analyzed by flow cytometry.
Staining of cells with anti-APO2.7 served as an additional marker for apoptotic mitochondria. This Ab was raised against apoptotic mitochondria and stains a p38 antigen exposed on apoptotic mitochondria (36) .
Preparation of Cytosolic Extracts-Cytosolic extracts were prepared from clones of wild-type or resistant Jurkat cells, as described previously (37) . Briefly, cultured Jurkat cells were washed twice with phosphate-buffered saline and then resuspended in ice-cold buffer (20 mM HEPES, pH 7.0, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM sodium EDTA, 1 mM sodium EGTA, 1 mM dithiothreitol, 250 mM sucrose, and protease inhibitors). After incubation on ice for 20 min, cells (2.5 ϫ 10 6 /0.5 ml) were disrupted by Dounce homogenization (20 strokes). Nuclei were removed by centrifugation at 650 ϫ g for 10 min at 4°C. Cellular extracts were obtained as the supernatants resulting from centrifugation at 14,000 ϫ g at 4°C for 30 min.
Caspase-3 activation was initiated by the addition of 10 M horse heart cytochrome c and 1 mM dATP to 10 l of cellular extract at 30°C for 1 h. To enforce processing of caspase-8, recombinant caspase-3 was added to the cell extracts. The extracts were boiled in sample buffer, resolved by SDS-PAGE, and immunoblotted for processing of caspases.
Western Blot Analysis-To generate whole cell extracts, cells were lysed in 1% Nonidet P-40, 20 mM Tris-base, pH 7.4, 137 mM NaCl, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, and 10 g/ml aprotinin. Proteins were resolved by SDS-PAGE and transferred to polyvinylidene difluoride membranes, as described previously (28, 30) . Following probing with a specific primary Ab and horseradish peroxidase-conjugated secondary Ab, the protein bands were detected by enhanced chemiluminescence (Pierce).
Subcellular Fractionation-After induction of apoptosis, Jurkat cells were harvested in isotonic mitochondrial buffer (20 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 10 g/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin) and Dounce-homogenized by 15-20 strokes (38) . Samples were transferred to Eppendorf centrifuge tubes and centrifuged at 650 ϫ g for 5 min at 4°C to eliminate nuclei and unbroken cells. The resulting supernatant was centrifuged at 10,000 ϫ g for 30 min at 4°C to obtain the heavy membrane pellet (HM). The supernatant was further centrifuged at 100,000 ϫ g for 1 h at 4°C to yield the final soluble cytosolic fraction, S-100. HM and S-100 subcellular fractions were assessed for the presence of cytochrome c by Western blot analysis.
Mitochondria Purification-Jurkat cells were suspended in mitochondria buffer (MIB) composed of 0.3 M sucrose, 10 mM MOPS, 1 mM EDTA, and 4 mM KH 2 PO 4 and lysed by Dounce homogenization as described previously (33) . Briefly, nuclei and debris were removed by 10 min of centrifugation at 650 ϫ g, and a pellet containing mitochondria was obtained by two successive spins at 10,000 ϫ g for 12 min. The washed mitochondria pellet was resuspended in MIB and layered on a Percoll gradient consisting of four layers of 10, 18, 30, and 70% Percoll in MIB. After centrifugation for 35 min at 13,500 ϫ g, the purified mitochondria were collected at the 30/70 interface. Mitochondria were diluted in MIB containing 1 mg/ml bovine serum albumin (at least a 10-fold dilution required to remove Percoll). The mitochondrial pellet was obtained by a 30-min spin at 20,000 ϫ g and used immediately in the cytochrome c release assay.
To assess insertion of Bax or tBid into the mitochondria membrane, purified mitochondria were treated with 0.1 M Na 2 CO 3 (pH 11.5) for 20 min on ice to remove alkali-sensitive proteins attached to the membrane (39) .
Cytochrome c Release Assay-Purified mitochondria (100 g of protein) were incubated with recombinant tBid or Bax at various doses as indicated in 20 l of MIB at 30°C for 30 min. Mitochondria were pelleted by centrifugation at 4000 ϫ g for 5 min. The resulting supernatants or mitochondria were mixed with lysis buffer and analyzed by SDS-PAGE and immunoblotting for the presence of cytochrome c. 
RESULTS
Cross-resistance to Fas-and VP-16-induced Apoptosis-Selected clonal T cell lines that survived in the presence of agonistic anti-Fas Ab were also found to be completely resistant to apoptotic signals of VP-16 known to initiate a mitochondrial cascade of apoptosis. The degree of resistance to apoptosis induced through the extrinsic or the intrinsic pathway was higher than that observed in Jurkat cells engineered to overexpress either CrmA or Bcl-2. While CrmA-overexpressing Jurkat cells were only partially resistant to Fas-mediated apoptosis, complete resistance was observed in the selected Jurkat cells (Fig. 1A) . As expected, CrmA-Jurkat cells were highly susceptible to VP-16-induced cell death, whereas the Fas-resistant Jurkat cells were as resistant to VP-16 as Jurkat cells overexpressing Bcl-2 (Fig. 1A ). These results demonstrate that the mechanism(s) responsible for resistance to apoptosis in the selected Jurkat cells regulate(s) the two known pathways of apoptosis. The cross-resistance to the two pathways of apoptosis was also demonstrated by flow cytometry. As shown in substrate for caspase-3 and -7 (28); and the anti-apoptosis proteins Bcl-2 and Bcl-xl, reported to convert to proapoptosis regulators following cleavage by caspase-3 (43, 44) . As demonstrated in Fig. 3 , no cleavage of any of the substrates tested was detected in resistant Jurkat cells treated with either anti-Fas Ab, VP-16, or staurosporin for 14 h.
Since caspase-8, the apical caspase of the Fas-apoptotic cascade, was not processed in resistant Jurkat clones in response to Fas cross-linking, we examined whether it would be processed by exogenously added caspase-3. Caspase-8 has been shown to be cleaved by caspase-3 downstream of mitochondrial damage induced by ␥-radiation (17) . As shown in Fig. 4 , processing of prodomain caspase-8 as well as the detection of the p20 subunit was similarly observed in extracts of either sensitive or resistant Jurkat cell lines treated with recombinant caspase-3.
Caspase-3 has been identified as an executioner caspase in both the Fas-and VP-16 apoptotic cascades. Therefore, we examined the processing of endogenous caspase-3 in resistant Jurkat cells in the presence of either exogenous recombinant caspase-8 or exogenous cytochrome c and dATP. As shown in Fig. 5 , caspase-3 subunits were detected in either sensitive or resistant Jurkat cells treated with recombinant caspase-8 or cytochrome c and dATP to enforce processing of prodomain caspase-3.
Fas-induced apoptosis in various cells is enhanced in the presence of metabolic inhibitors such as cycloheximide (45) . To investigate whether an endogenous protein inhibitor was involved in the observed resistance to the Fas-apoptotic cascade, wild-type and resistant Jurkat cells were treated with cycloheximide prior to the addition of anti-Fas Ab. While an increased percentage of apoptotic cells was detected in sensitive Jurkat cells, this combined treatment did not induce apoptosis in resistant Jurkat cells (data not shown). These observations were further confirmed by assessment of caspase-8 processing. Combined treatment of cycloheximide and anti-Fas Ab did not result in any processing of caspase-8 in resistant cells, while it significantly enhanced the processing seen in wild-type Jurkat cells (data not shown). These findings suggest that the observed block in caspase-8 processing was not mediated by an endogenously metabolized inhibitor.
To further identify the site of blockage, we investigated whether caspase-8 would be processed in response to signals via other death receptors known to use caspase-8 activation as an apical event in their cascade (46) . To this end, sensitive and resistant Jurkat cells were cross-linked by TRAIL (100 ng/ml; enhancer, 2 g/ml) for 14 h at 37°C. No processing of caspase-8 was detected in resistant cells, whereas similar TRAIL crosslinking induced marked processing in sensitive cells (data not shown). The arrest in caspase-8 activation in both Fas and TRAIL receptor cascades, suggests that the block in the apoptotic cascade in resistant cells is at the level of caspase-8 and not at the receptor level. The block in caspase-8 activation was not mediated by up-regulated expression of FLICE/caspase-8 Inhibitory Protein (FLIP), since similar levels of FLIP-short or FLIP-long proteins were detected in sensitive and resistant Jurkat cells (data not shown). Also, similar levels of FADD expression were detected in sensitive and resistant Jurkat cells (data not shown). 6A). These results suggest that alterations in permeability transition in response to VP-16 are blocked in resistant Jurkat cells.
Lack of Apoptosis-associated Alterations in Mitochondria of
We also assessed mitochondrial changes by NAO, a mitochondria-specific dye, which is independent of permeability transition. NAO is a probe that interacts specifically with nonoxidized cardiolipin, a lipid that is exclusively localized in the inner mitochondrial membrane (35) . Loss in cardiolipin, indicating loss in mitochondria matrix integrity, was detected in sensitive cells but not in resistant cells treated with either anti-Fas Ab or VP-16 (Fig. 6B) . Also, no generation of reactive oxygen species was detected in resistant Jurkat cells, as assessed by flow cytometric analysis of HE staining (Fig. 6C) .
It has been reported that the mAb APO2.7 detects an apoptosis-associated increase in expression of a p38 mitochondrial antigen (36) . A population of cells expressing this antigen was detected in sensitive, but not in resistant, Jurkat cells following Fas or VP-16 stimulation (Fig. 6D) . These results suggest that the block in the VP-16-induced cascade is at the level of the mitochondria, since mitochondria-specific apoptotic events did not occur in resistant Jurkat cells treated with VP-16.
Involvement of the mitochondria in apoptosis has been associated with release of cytochrome c to the cytoplasm, where it initiates a caspase cascade (5, 6) . Indeed, in wild-type Jurkat cells treated with either anti-Fas Ab or VP-16, translocation of cytochrome c to the cytosol was observed (Fig. 7) . However, no cytochrome c release was detected in resistant Jurkat cells treated by each of these stimuli. These observations suggest that in resistant Jurkat cells the apoptotic mechanism responsible for cytochrome c release is blocked.
Analysis of Intermembrane Protein Release from Purified Mitochondria-It has recently been reported that the recombinant proteins, Bax and tBid, induce cytochrome c release when directly applied to purified mitochondria. To further characterize the block in cytochrome c release in resistant cells treated with VP-16, we investigated the response of purified mitochondria from sensitive and resistant Jurkat cells to recombinant Bax (GST-Bax⌬TM) or tBid (His-tBid). These recombinant proteins have been previously demonstrated to efficiently induce cytochrome c release from mitochondria (47) (48) (49) (50) (51) (52) . Purified mitochondria from sensitive or resistant Jurkat cells were incubated for 30 min at 30°C with recombinant Bax or tBid. Following removal of mitochondria, the resulting supernatant was tested by immunoblot analysis for the presence of cytochrome c. As expected, cytochrome c was released from mitochondria obtained from sensitive Jurkat cells in response to either exogenous recombinant Bax or tBid (Fig. 8, A and B) . No release of cytochrome c was detected in supernatants of resistant mitochondria treated with these recombinant proteins. These results suggest that the mitochondrial mechanism responsible for release of cytochrome c in response to Bid, Bax, or cell stimulation with VP-16 is impaired in mitochondria of resistant Jurkat cells.
To evaluate whether the resistance mechanism was specific for cytochrome c or applied also to other intermembrane proteins, we examined release of AIF from sensitive and resistant mitochondria in response to recombinant tBid. As shown in Fig. 8C , AIF was released from sensitive, but not resistant, mitochondria. These results suggest that the mitochondrial mechanism responsible for release of intermembrane proteins is blocked in resistant Jurkat cells.
To assess the ability of endogenous Bax or tBid to translocate to the mitochondria, we examined the expression of these proteins within the mitochondria of resistant cells. To this end, purified mitochondria from sensitive and resistant Jurkat cells were treated with 0.1 M Na 2 CO 3 (pH 11.5) for 20 min on ice, to remove alkali-sensitive proteins that are attached but not inserted into the mitochondrial outer membrane (39) . The presence of Bax within the alkali-resistant fraction of the treated mitochondria was tested for by Western blot analysis. As shown in Fig. 9A , similar levels of endogenous Bax were expressed in mitochondria of sensitive or resistant Jurkat cells. The expression of mitochondrial VDAC and the absence of cytosolic ␤-actin in the alkalitreated mitochondria (Ins) further suggest that the fractions tested represent pure mitochondria, and therefore, the translocation of endogenous Bax to the mitochondria is not impaired in resistant cells. These results also demonstrate that in Jurkat cells, as shown previously for HeLa cells (39) and for the hematopoietic cells FL5.12 (53), a basal level of Bax is present within the mitochondria prior to induction of apoptosis. To assess the presence of endogenous tBid in the mitochondria, extracts of sensitive or resistant Jurkat cells were treated with recombinant caspase-8 (100 nM) for 1 h at 37°C to generate endogenous tBid. The extracts were then separated into cytosol (S-100) and mitochondria (HM). As shown in Fig. 9B , endogenous tBid (15 kDa) generated by exogenous recombinant caspase-8 was detected in mitochondrial fractions from both sensitive and resistant Jurkat cells. The use of ␤-actin as a marker for cytosolic proteins and VDAC as a marker for mitochondrial outer membrane proteins provides evidence for the presence of endogenous tBid in the mitochondria. To further determine whether exogenous tBid added to purified mitochondria could translocate into the mitochondria, purified mitochondria from sensitive or resistant Jurkat cells were incubated with recombinant tBid for 30 min at 37°C. The mitochondria were then treated with 0.1 M Na 2 CO 3 , and alkali-sensitive (attached) or alkaliresistant (membrane-inserted) fractions were assessed for the presence of tBid by Western blot analysis. As demonstrated in Fig. 9C , tBid was found inserted into the mitochondria membrane in both sensitive and resistant cells. In these studies, cytochrome c oxidase IV, a mitochondrial inner membrane enzyme, and VDAC, a mitochondrial outer membrane protein, served as markers for the mitochondrial matrix as well as a gel loading control. These results suggest that the block in cytochrome c or AIF release in resistant mitochondria is not mediated by impaired translocation of either Bax or tBid to the mitochondria.
DISCUSSION
In the present study, we describe the selection of Jurkat leukemic T cells resistant to an intrinsic apoptotic pathway via elimination of cells susceptible to the extrinsic Fas-mediated apoptotic cascade. The block in the Fas cascade appears to be at the level of caspase-8, since no processing or activation of caspase-8 was observed following cross-linking of either Fas or TRAIL receptors, which were expressed at a similar level on sensitive and resistant cells. However, caspase-8 in resistant cells was processed in the presence of active recombinant caspase-3, suggesting that it is potentially activable. Activation of caspase-8 was not suppressed by up-regulation in expression of either FLIP-long or FLIP-short or by a differential expression of FADD, since similar levels of these proteins were detected in all sensitive and resistant clones. The resistance to Fas-mediated apoptosis and the block in caspase-8 activation was not affected by pretreatment of the cells with cycloheximide, a metabolism inhibitor that significantly increased susceptibility of sensitive Jurkat cells to Fas-mediated apoptosis. Although these findings suggest that caspase-8 inhibition is not mediated by a metabolized protein inhibitor, the mechanism responsible for the block in caspase-8 activation in these resistant cells is not yet known. It is possible that additional regulatory components may be involved in the activation of caspase-8, which are yet to be identified. Since caspase-8, the apical caspase in the death receptor cascade, was not activated, it was expected that downstream apoptotic events would not be executed. It was, however, surprising that elimination of Fassusceptible T cells by anti-Fas Ab would result in selection of cells resistant to intrinsic apoptotic pathways.
The block in the intrinsic cascade was localized to the mitochondria, since no apoptosis-associated alterations were detected in resistant mitochondria treated with VP-16. We tested a broad range of mitochondrial apoptotic events, including changes in the inner membrane, the outer membrane, and the mitochondrial matrix. No changes in inner membrane permeability transition, loss of mitochondrial inner membrane cardiolipin, or reactive oxygen species generation were detected in resistant cell mitochondria. Further, we identified a block in the mechanism responsible for cytochrome c release in response to an apoptotic signaling by VP-16 or in cell-free mitochondria treated with recombinant Bax or tBid. The abrogation in release of cytochrome c was not due to impaired translocation of either Bax or tBid to the mitochondria. These proapoptotic Bcl-2 family members were found inserted, rather than attached, to the resistant mitochondria. The block in cytochrome c release applies also to another intermembrane protein, AIF, reported to be released in response to apoptotic signaling (54, 55) . Our results suggest that the block in resistant mitochondria to specific death stimulation localizes to the mechanism responsible for generating specific pores in the outer mitochondrial membrane, which allow translocation of intermembrane proteins to the cytosol.
According to the currently accepted notion, which is based on genetic studies in knockout mouse models (7-10, 12) , the initiation phases of the extrinsic and the intrinsic pathways of apoptosis are independent. Cross-talk between the pathways would occur mainly as an amplification loop once the cascade shown. The blot membrane was stripped and reprobed with anti-VDAC mAb, stripped again, and probed with anti-␤-actin. No ␤-actin was detected in purified mitochondria following alkali treatment (not shown). B, extracts of sensitive or resistant Jurkat cells were treated with recombinant caspase-8 (100 nM) for 1 h at 37°C. The extracts were separated into cytosol (S-100) and mitochondrial (HM) fractions as described under "Experimental Procedures." These two cellular fractions were resolved by SDS-PAGE and probed by immunoblotting for the presence of tBid. The blot membrane was stripped and reprobed with anti-␤-actin mAb and subsequently with anti-VDAC mAb, which served as cellular fractionation controls. C, purified mitochondria from sensitive or resistant Jurkat cells were incubated with recombinant His-tBid (100 nM) for 1 h at 30°C. Treated and untreated mitochondria were washed in MIB and further treated with 0.1 M Na 2 CO 3 (pH 11.5) for 20 min on ice. Alkali-sensitive (attached (Att)) and alkali-resistant (insert (Ins)) fractions were lysed, resolved by SDS-PAGE, and immunoblotted for the presence of tBid. The membrane was stripped and reprobed with anti-cytochrome c oxidase IV Ab and subsequently with anti-VDAC mAb as markers for mitochondrial matrix and as loading controls.
has been initiated. Fas-induced apoptosis is mediated either by direct activation of downstream effector caspases or via Bidinduced mitochondrial pathway (40) . Thus, the observed crossresistance of Jurkat clones to Fas-and VP-16-mediated apoptosis may be explained as two independent mechanisms involved in blocking the initiation of two independent pathways. Since the entire study was performed in clonal cell lines derived by limiting dilution, each of the clones would encompass two independent mechanisms of resistance. It is possible that in initial selection against cells susceptible to Fas signaling, accumulation of type II cells dependent on mitochondria for their Fas-mediated apoptosis took place (56) , whereas continuous selection resulted in cells deficient in mitochondrial mechanism for releasing intermembrane proteins.
The identification of BAR, an apoptosis regulator, which can mediate cross-talk between components of the "independent" pathways, may suggest that in certain cells or apoptotic conditions, common regulators of the two pathways may be functional. BAR was identified by using a yeast-based screen for inhibitors of Bax-induced cell death (57) . The BAR protein contains a SAM domain, which is required for its interaction with Bcl-2 and Bcl-XL and for suppression of Bax-induced cell death in both mammalian cells and yeast. In addition, BAR contains a DED-like domain responsible for its interaction with DED-containing procaspases and suppression of Fasinduced apoptosis. Furthermore, BAR can bridge procaspase-8 and Bcl-2 into a protein complex. Since BAR may serve as an inhibitor of Bax and at the same time bind to procaspase-8, we examined by reverse transcription-polymerase chain reaction its level of expression in sensitive and resistant Jurkat cells. We detected similar levels of BAR mRNA in sensitive and resistant Jurkat cells (data not shown), suggesting that BAR is not involved in the mechanism of resistance in the Jurkat cells.
A Fas-interacting serine/threonine kinase capable of inducing phosphorylation of FADD has recently been identified as one of the homeodomain-interacting protein kinases (homeodomain-interacting protein kinase 3) involved in regulation of apoptosis via p53 (58, 59) . It is conceivable that such a common regulator of both apoptotic pathways may be linked to the observed mechanism of cross-resistance (58) .
A common regulator of Fas-and ␥-irradiation-induced apoptotic cascade was also suggested in a previous study (60) . Clones of Jurkat cells were reported to have a deficiency in caspase-8 activation in response to Fas cross-linking and in cytochrome c release following irradiation. In the present study, we identified the mitochondrial mechanism responsible for the release of intermembrane proteins as the target of the block observed in the intrinsic apoptotic cascade. The biochemical nature of this block and the mechanism responsible for the cross-resistance between the mitochondrial and the death receptor cascades remain to be elucidated.
